Transcranial magnetic stimulation as a tool to understand genetic conditions associated with epilepsy

Katri SilvennoinenSimona BalestriniJohn C. RothwellSanjay M. Sisodiya

First published: 12 August 2020 https://doi.org/10.1111/epi.16634

Funding Information:

This study was supported by EC grant 279062, EpiPGX. This work was partly carried out at NIHR University College London Hospitals Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme. Additional funding was provided by the Epilepsy Society. KS is supported by a Wellcome Trust Strategic Award (WT104033AIA). TMS work is additionally supported by grant funding from UCB to Epilepsy Society.

epi.16634

0 0 votes
Article Rating
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Related Post

Alternating Hemiplegia of Childhood: gastrointestinal manifestations and correlation with neurological impairmentsAlternating Hemiplegia of Childhood: gastrointestinal manifestations and correlation with neurological impairments

Milton Pratt,  Julie Uchitel,  Nancy McGreal,  Kelly Gordon,  Lyndsey Prange,  Melissa McLean,  Richard J. Noel,  Blaire Rikard,  Mary K. Rogers Boruta &  Mohamad A. Mikati  Orphanet Journal of Rare Diseases volume 15, Article number: 231 (2020) 

AHC Clinical Research in the UKAHC Clinical Research in the UK

The AHC and ATP1A3 Natural History Study  We would love to hear from you!   Alternating Hemiplegia of Childhood (AHC) is an ultra-rare disease with an estimated one in a million occurrence. Patients suffer from a combination of disabling paroxysmal events (hemiplegic or dystonic attacks and, in some cases, epileptic seizures) and varying degrees of permanent neurologic features (ataxia, dystonia, neurocognitive delay,  mental health problems). It is a disabling condition that impacts severely on the quality of life of the affected individual and their families.  About 75% of the patients have a mutation in the gene ATP1A3, in the others the cause of AHC is mostly unknown.  Curative therapies are not as yet available and the medications used to alleviate symptoms like hemiplegia, dystonia, and seizures are helpful for some, but not all patients. As long-term follow-up studies are lacking, clinicians cannot provide families with an accurate prognosis. Driven by our inability to substantially help our growing cohort of afflicted patients, and with the support of AHCUK,  the UK support group, we have set up the AHC and ATP1A3 natural history study led by Professor Helen Cross and Dr. Katerina Vezyroglou at Great Ormond Street Hospital in London.  The study aims to answer some of the unanswered questions about AHC, such as Why are different patients affected differently? Can MRI and EEG help us predict the severity of the disease? What causes AHC in patients without a ATP1A3 mutation?   All patients (children and adults) with AHC or/and with a mutation in  ATP1A3 are welcome to participate.  If you have questions or are interested to find out more, please get in touch at k.vezyroglou@ucl.ac.uk   While viewing the pdf attached

0
Would love your thoughts, please comment.x
()
x